Aim:In this study,we would like to determine associations between β2-Adrenergic Receptor(β2AR)polymorphisms at codon 16 and 27 and the response to short acting β2-agonist during asthmatic exacerbation.Methods:This ...Aim:In this study,we would like to determine associations between β2-Adrenergic Receptor(β2AR)polymorphisms at codon 16 and 27 and the response to short acting β2-agonist during asthmatic exacerbation.Methods:This was a prospective cross-sectional study of one year duration.One hundred and thirty two asthmatic patients were recruited.Five mls of venous blood was taken for DNA extraction and then genotyped for the β2AR polymorphisms using multiplex PCR.Patient's clinical responses to β2-agonist nebulization were then compared to their genotype to determine the association.Results:We found that there was no association between β2AR polymorphisms at both codon 16 and 27 with response towards short acting β2-agonist,P=0.315 and P=0.706 respectively.Conclusion:We suggested that β2AR polymorphisms at both codon 16 and 27 had no influent on the response to short acting β2-agonist.展开更多
Objective To observe effects of medication use on small airway function,airway inflammation and acute exacerbations in patients with clinically controlled asthma.Methods Forced expiratory flow over the middle half of ...Objective To observe effects of medication use on small airway function,airway inflammation and acute exacerbations in patients with clinically controlled asthma.Methods Forced expiratory flow over the middle half of the forced expiratory curve(FEF25%–75%),percentage of eosinophil,concentrations of eosinophil cationic protein(ECP)and interleukin(IL)-5 in induced sputum were assessed in patients with clinically controlled asthma who were given oral anti-inflammatory agents alone or in combination with inhaled therapy and inhaled therapy alone.Subsequently,acute exacerbations were compared between two groups during the 24-week follow-up period.Results FEF25%–75%in 43 patients with clinically controlled asthma given oral anti-inflammatory agents alone or in combination with inhaled therapy was significantly higher than that in 49 patients given inhaled therapy alone.Meanwhile,the percentage of eosinophils and levels of IL-5 and ECP in patients with clinically controlled asthma given oral anti-inflammatory agents alone or in combination with inhaled therapy were significantly lower than those in patients given inhaled therapy alone.Additionally,the patients with clinically controlled asthma given inhaled therapy were likely to have more acute exacerbation than the patients given oral anti-inflammatory agents alone or in combination with inhaled therapy during the 24-week follow-up period.Conclusion Systemic anti-inflammatory agents may have a greater effect on parameters reflecting small airway patency and reducing acute exacerbations,presumably secondary to reduction in airway inflammation.展开更多
目的观察苏沈九宝汤治疗支气管哮喘急性发作期的临床疗效和对Th1/Th2因子的影响。方法选取2022年2月至2023年5月于浙江中医药大学附属四省边际中医院诊治的98例支气管哮喘急性发作期患者,根据随机数字表法将其分为治疗组和对照组,每组...目的观察苏沈九宝汤治疗支气管哮喘急性发作期的临床疗效和对Th1/Th2因子的影响。方法选取2022年2月至2023年5月于浙江中医药大学附属四省边际中医院诊治的98例支气管哮喘急性发作期患者,根据随机数字表法将其分为治疗组和对照组,每组各49例。对照组患者给予吸氧、雾化等常规治疗,治疗组患者在对照组基础上加用苏沈九宝汤。比较两组患者的临床疗效、中医证候积分、肺功能指标[第一秒用力呼气量(forced expiratory volume in first second,FEV1)、呼气流量峰值(peak expiratory flow,PEF)]和实验室指标[白细胞介素(interleukin,IL)-4、IL-13、γ干扰素(interferon-γ,IFN-γ)、免疫球蛋白E(immunoglobulin E,IgE)]。结果治疗组患者的总有效率显著高于对照组(χ^(2)=9.287,P=0.010);治疗后,两组患者的中医证候积分、血清IL-4、IL-13、IgE水平均显著低于本组治疗前,FEV_(1)、PEF、IFN-γ水平均显著高于本组治疗前(P<0.05),治疗组患者的中医证候积分、血清IL-4、IL-13、IgE水平均显著低于对照组,FEV1、PEF、IFN-γ水平均显著高于对照组(P<0.05)。结论苏沈九宝汤治疗支气管哮喘急性发作,可显著提高临床疗效,降低患者的炎症因子水平,改善肺功能。展开更多
目的系统评价孟鲁司特治疗成人哮喘急性发作的疗效和安全性。方法计算机检索Pubmed、Embase、Web of Science、OVID和Cochrane图书馆等电子数据库,查找应用孟鲁司特与安慰剂治疗成人哮喘急性发作期患者的随机对照试验(RCT)。对符合条件...目的系统评价孟鲁司特治疗成人哮喘急性发作的疗效和安全性。方法计算机检索Pubmed、Embase、Web of Science、OVID和Cochrane图书馆等电子数据库,查找应用孟鲁司特与安慰剂治疗成人哮喘急性发作期患者的随机对照试验(RCT)。对符合条件的RCT,由2名研究者独立进行资料提取和质量评价,采用RevMan 5.1软件进行Meta分析,采用GRADE指南对证据质量和等级推荐进行分级,计算相关临床结局的需要处理的例数(NNT)。结果共纳入5个RCT(n=947)的成人哮喘急性发作患者。Meta分析结果显示,与安慰剂比较,孟鲁司特能明显改善哮喘急性发作的呼气峰流速(MD=10.65[2.81,18.49],P=0.008)和减少全身糖皮质激素的使用(RR=0.75[0.62,0.92],NNT=7[4,46],P=0.005),但在减少住院治疗(RR=0.78[0.57,1.06],NNT=19[9,+∞],P=0.110)及治疗失败(RR=0.85[0.67,1.09],NNT=17[9,+∞],P=0.314)方面差异无统计学意义。GRADE证据级别及推荐强度结果显示,证据水平为低～中等,推荐等级为弱推荐。结论孟鲁司特能改善哮喘急性发作时的肺功能,且可减少口服糖皮质激素使用,而有关减少住院治疗和治疗失败的临床疗效有待进一步研究。展开更多
目的:探讨布地奈德福莫特罗对轻中度支气管哮喘急性发作患者肺通气功能及预后的影响。方法:89例轻中度支气管哮喘急性发作患者随机分为研究组(45例)和对照组(44例)。研究组患者给予布地奈德福莫特罗干粉吸入剂1吸,每6 h 1次,每次吸药后...目的:探讨布地奈德福莫特罗对轻中度支气管哮喘急性发作患者肺通气功能及预后的影响。方法:89例轻中度支气管哮喘急性发作患者随机分为研究组(45例)和对照组(44例)。研究组患者给予布地奈德福莫特罗干粉吸入剂1吸,每6 h 1次,每次吸药后均反复漱口5次,每日不超过6吸+孟鲁司特片10 mg,口服,每晚1次。对照组患者给予强的松片25 mg,d_(1-5),早餐后口服,每日1次+茶碱缓释胶囊0.2 g,口服,每日2次+孟鲁司特片10 mg,口服,每晚1次。两组疗程均为5 d。观察两组患者治疗前后急性哮喘生活质量问卷(AQLQ)评分、第1秒用力呼气量(FEV1)、呼气峰流速占预计值百分比(PEF%pred)、血氧饱和度(SpO_2),并记录不良反应发生情况。结果:治疗前,两组患者急性AQLQ评分、FEV1、PEF%pred、SpO_2比较,差异均无统计学意义(P>0.05)。治疗后,两组患者急性AQLQ评分、FEV1、PEF%pred、SpO_2均显著高于同组治疗前,差异均有统计学意义(P<0.05);但两组间比较差异无统计学意义(P>0.05)。研究组患者不良反应发生率显著低于对照组,差异有统计学意义(P<0.05)。结论:布地奈德福莫特罗可显著改善轻中度支气管哮喘急性发作患者的肺通气功能及预后,且安全性较好。展开更多
基金This project was carried out under the financial support of USM short-term grant(304/PPSP/6131324)
文摘Aim:In this study,we would like to determine associations between β2-Adrenergic Receptor(β2AR)polymorphisms at codon 16 and 27 and the response to short acting β2-agonist during asthmatic exacerbation.Methods:This was a prospective cross-sectional study of one year duration.One hundred and thirty two asthmatic patients were recruited.Five mls of venous blood was taken for DNA extraction and then genotyped for the β2AR polymorphisms using multiplex PCR.Patient's clinical responses to β2-agonist nebulization were then compared to their genotype to determine the association.Results:We found that there was no association between β2AR polymorphisms at both codon 16 and 27 with response towards short acting β2-agonist,P=0.315 and P=0.706 respectively.Conclusion:We suggested that β2AR polymorphisms at both codon 16 and 27 had no influent on the response to short acting β2-agonist.
基金supported by the National Natural Science Foundation of China(No.81970024).
文摘Objective To observe effects of medication use on small airway function,airway inflammation and acute exacerbations in patients with clinically controlled asthma.Methods Forced expiratory flow over the middle half of the forced expiratory curve(FEF25%–75%),percentage of eosinophil,concentrations of eosinophil cationic protein(ECP)and interleukin(IL)-5 in induced sputum were assessed in patients with clinically controlled asthma who were given oral anti-inflammatory agents alone or in combination with inhaled therapy and inhaled therapy alone.Subsequently,acute exacerbations were compared between two groups during the 24-week follow-up period.Results FEF25%–75%in 43 patients with clinically controlled asthma given oral anti-inflammatory agents alone or in combination with inhaled therapy was significantly higher than that in 49 patients given inhaled therapy alone.Meanwhile,the percentage of eosinophils and levels of IL-5 and ECP in patients with clinically controlled asthma given oral anti-inflammatory agents alone or in combination with inhaled therapy were significantly lower than those in patients given inhaled therapy alone.Additionally,the patients with clinically controlled asthma given inhaled therapy were likely to have more acute exacerbation than the patients given oral anti-inflammatory agents alone or in combination with inhaled therapy during the 24-week follow-up period.Conclusion Systemic anti-inflammatory agents may have a greater effect on parameters reflecting small airway patency and reducing acute exacerbations,presumably secondary to reduction in airway inflammation.
文摘目的观察苏沈九宝汤治疗支气管哮喘急性发作期的临床疗效和对Th1/Th2因子的影响。方法选取2022年2月至2023年5月于浙江中医药大学附属四省边际中医院诊治的98例支气管哮喘急性发作期患者,根据随机数字表法将其分为治疗组和对照组,每组各49例。对照组患者给予吸氧、雾化等常规治疗,治疗组患者在对照组基础上加用苏沈九宝汤。比较两组患者的临床疗效、中医证候积分、肺功能指标[第一秒用力呼气量(forced expiratory volume in first second,FEV1)、呼气流量峰值(peak expiratory flow,PEF)]和实验室指标[白细胞介素(interleukin,IL)-4、IL-13、γ干扰素(interferon-γ,IFN-γ)、免疫球蛋白E(immunoglobulin E,IgE)]。结果治疗组患者的总有效率显著高于对照组(χ^(2)=9.287,P=0.010);治疗后,两组患者的中医证候积分、血清IL-4、IL-13、IgE水平均显著低于本组治疗前,FEV_(1)、PEF、IFN-γ水平均显著高于本组治疗前(P<0.05),治疗组患者的中医证候积分、血清IL-4、IL-13、IgE水平均显著低于对照组,FEV1、PEF、IFN-γ水平均显著高于对照组(P<0.05)。结论苏沈九宝汤治疗支气管哮喘急性发作,可显著提高临床疗效,降低患者的炎症因子水平,改善肺功能。
文摘目的系统评价孟鲁司特治疗成人哮喘急性发作的疗效和安全性。方法计算机检索Pubmed、Embase、Web of Science、OVID和Cochrane图书馆等电子数据库,查找应用孟鲁司特与安慰剂治疗成人哮喘急性发作期患者的随机对照试验(RCT)。对符合条件的RCT,由2名研究者独立进行资料提取和质量评价,采用RevMan 5.1软件进行Meta分析,采用GRADE指南对证据质量和等级推荐进行分级,计算相关临床结局的需要处理的例数(NNT)。结果共纳入5个RCT(n=947)的成人哮喘急性发作患者。Meta分析结果显示,与安慰剂比较,孟鲁司特能明显改善哮喘急性发作的呼气峰流速(MD=10.65[2.81,18.49],P=0.008)和减少全身糖皮质激素的使用(RR=0.75[0.62,0.92],NNT=7[4,46],P=0.005),但在减少住院治疗(RR=0.78[0.57,1.06],NNT=19[9,+∞],P=0.110)及治疗失败(RR=0.85[0.67,1.09],NNT=17[9,+∞],P=0.314)方面差异无统计学意义。GRADE证据级别及推荐强度结果显示,证据水平为低～中等,推荐等级为弱推荐。结论孟鲁司特能改善哮喘急性发作时的肺功能,且可减少口服糖皮质激素使用,而有关减少住院治疗和治疗失败的临床疗效有待进一步研究。
